Balanced news tone
News Sentiment
HURA sentiment intelligence
TuHURA Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
48
Balanced news tone
58 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-2.0% over one week, +3.0% over four weeks, trend active, and below fair value.
Form DEF 14A TuHURA Biosciences For: 9 July By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
78/100 classification
One-week reaction
-2.0%
Price reacting lower
Trend fit
Trend active
3.0% over four weeks
Fair value
-86.2%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
6
Neutral
42
Negative
10
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Investing.com Nigeria
Direct company coverage
Form DEF 14A TuHURA Biosciences For: 9 July By Investing.com
Investing.com reports that TuHURA Biosciences filed a Form DEF 14A on July 9. The article provides this concise financial news, attributing the information to Reuters. It does not elaborate on the contents or implications of the filing.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 22:11
- Source
- Investing.com Nigeria
Moomoo
Direct company coverage
TuHURA Biosciences (HURA) Stock Forum and Discussion
This article provides a forum for discussion regarding TuHURA Biosciences (HURA) stock. Investors and interested parties can use this platform to share insights and opinions about the company's performance and future prospects.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 04:40
- Source
- Moomoo
Minichart
Direct company coverage
TuHURA Biosciences, Inc. (NASDAQ: HURA) Files 8-K Report Detailing Company Information and Compliance Updates – Minichart
TuHURA Biosciences, Inc. (NASDAQ: HURA) has filed an 8-K report detailing a new direct financial obligation and referencing a prior loan agreement from April 22, 2026. The report emphasizes the company's dependency on this loan for capital, noting potential risks due to the lende
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 08 Jul 2026 03:40
- Source
- Minichart
www.marketscreener.com
Direct company coverage
TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell 3000E Growth Benchmark
TuHURA Biosciences, Inc. (NasdaqCM:HURA) has been removed from the Russell 3000E Growth Benchmark, as announced on June 28, 2026. This follows several other removals from various Russell indices around the same date, including the Russell 2000, Russell 3000, and Russell 2500 indi
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 02 Jul 2026 18:12
- Source
- www.marketscreener.com
www.marketscreener.com
Direct company coverage
TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2000 Dynamic Index
TuHURA Biosciences, Inc. (NasdaqCM: HURA) has been removed from the Russell 2000 Dynamic Index, as well as several other Russell indices, including the Russell 3000E, Russell Small Cap Completeness, Russell 2500, Russell 3000, Russell 2000, and Russell Small Cap Comp Growth Bench
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 29 Jun 2026 21:39
- Source
- www.marketscreener.com
TradingView
Direct company coverage
Enterprise value to EBIT forward of TuHURA Biosciences, Inc. – FWB:PL3
This article displays financial information for TuHURA Biosciences, Inc. under its Frankfurt Stock Exchange ticker FWB:PL3. Specifically, it presents the company's enterprise value to EBIT forward, noting that the market is currently closed with no trades. The content primarily s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 15:39
- Source
- TradingView
www.marketscreener.com
Direct company coverage
TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2500 Index
TuHURA Biosciences, Inc. (NasdaqCM: HURA) has been removed from the Russell 2500 Index as of June 29, 2026. This exclusion is one of several recent removals from various Russell indices, including the Russell 2000 Dynamic, 3000E, Small Cap Completeness, 3000, 2000, and Small Cap
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 29 Jun 2026 13:46
- Source
- www.marketscreener.com
www.marketscreener.com
Direct company coverage
TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell Small Cap Comp Growth Benchmark
TuHURA Biosciences, Inc. (NasdaqCM:HURA) has been removed from the Russell Small Cap Comp Growth Benchmark. This news follows several recent developments for the company, including filing a New Drug Application for an antibody to treat AML and reporting Q1 2026 earnings results.
- Tone
- Negative 28/100
- Event
- Earnings
- Published
- 29 Jun 2026 10:11
- Source
- www.marketscreener.com
www.marketscreener.com
Direct company coverage
TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 3000 Index
TuHURA Biosciences, Inc. (NasdaqCM: HURA) has been removed from the Russell 3000 Index, according to an announcement published on June 29, 2026, at 10:11 am EDT, based on S&P Capital IQ data. This change is part of broader index adjustments, as the company was also dropped from s
- Tone
- Negative 20/100
- Event
- Market update
- Published
- 29 Jun 2026 10:11
- Source
- www.marketscreener.com
TradingView
Direct company coverage
Price to earnings forward of TuHURA Biosciences, Inc. – DUS:PL3
This article provides the "Price to earnings forward" value for TuHURA Biosciences, Inc., identified by its Dusseldorf Stock Exchange symbol DUS:PL3. The content indicates that the market is closed, and no trades have occurred for this specific financial metric. The information i
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 13:41
- Source
- TradingView
TradingView
Direct company coverage
Return on equity % of TuHURA Biosciences, Inc. – DUS:PL3
This article provides financial information for TuHURA Biosciences, Inc. (DUS:PL3) on the TradingView platform. It specifically focuses on the company's Return on Equity (%) metric. The content highlights that market is currently closed with no trades and lists various sections a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 01:09
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of TuHURA Biosciences, Inc. – NASDAQ:HURA
This article provides financial information for TuHURA Biosciences, Inc. (NASDAQ:HURA), specifically focusing on its enterprise value to EBITDA forward. While the article text itself is minimal, it highlights access to detailed financial data and other market information for the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 22:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of TuHURA Biosciences, Inc. – NASDAQ:HURA
This article provides the enterprise value to revenue forward for TuHURA Biosciences, Inc. (NASDAQ: HURA). It presents financial data within a TradingView context, displaying the stock's performance and related information like historical financials, news, and community insights.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 18:40
- Source
- TradingView
TradingView
Direct company coverage
TuHURA Biosciences, Inc. Balance Sheet – DUS:PL3
TuHURA Biosciences, Inc.'s balance sheet for Q1 2026 shows total assets of 25.71 million EUR, a 10.40% increase from Q4 2025. Total liabilities also increased by 3.15% to 5.64 million EUR in the same quarter. The report provides a snapshot of the company's financial position and
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 11:40
- Source
- TradingView
Stock Titan
Direct company coverage
TuHURA Biosciences (HURA) virtual annual meeting Aug 18; shareholders to vote on 1.88M-share issuance
TuHURA Biosciences will hold its virtual annual meeting on August 18, 2026, where shareholders will vote on several proposals, including the election of six directors and the approval of issuing 1.88 million shares to Parkview Holdings One LLC. This share issuance is in connectio
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 Jun 2026 21:40
- Source
- Stock Titan
TradingView
Direct company coverage
TuHURA Biosciences, Inc. Actuals & Estimates (NASDAQ:HURA)
This article provides an overview of TuHURA Biosciences, Inc. (NASDAQ: HURA) stock performance, financial estimates, and analyst forecasts. It details the company's current stock price, market capitalization, historical highs and lows, and upcoming earnings report dates, while al
- Tone
- Negative 38/100
- Event
- Earnings
- Published
- 26 Jun 2026 06:40
- Source
- TradingView
TradingView
Direct company coverage
TuHURA Biosciences, Inc. Actuals & Estimates (MUN:PL3)
This article provides an overview of TuHURA Biosciences, Inc. (MUN:PL3) financials, including actual reported data and analyst estimates. It covers historical stock performance like all-time high and low prices, upcoming earnings dates, and past earnings and revenue figures. Addi
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 01:40
- Source
- TradingView
TradingView
Direct company coverage
PL3 Forecast — Price Target — Prediction for 2027
This article provides a forecast for TuHURA Biosciences, Inc. (PL3) stock, including price targets and analyst ratings. It highlights the stock's highest and lowest prices, upcoming earnings reports, and financial performance such as EPS, revenue, and net income. The article also
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 19:12
- Source
- TradingView
Minichart
Direct company coverage
TuHURA Biosciences, Inc. Files Form 8-K with Nasdaq: Corporate Information, Address, and Key Details
TuHURA Biosciences, Inc. (NASDAQ: HURA) announced significant updates regarding its 2026 Annual Meeting of Stockholders, which will be held virtually on August 18, 2026. Due to this change, the deadline for shareholder proposals and director nominations for proxy materials has be
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 03:10
- Source
- Minichart
TradingKey
Direct company coverage
TuHURA Biosciences Inc (HURA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for TuHURA Biosciences Inc (HURA). It notes that no dividends have been distributed in the past five years. The stock split section details several merger-related stock splits with a ratio of 35→1 in October 20
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 01:10
- Source
- TradingKey
TradingKey
Direct company coverage
TuHURA Biosciences Inc (HURA) Valuation: PE, PB & Fair Value Analysis
This article provides a brief valuation analysis for TuHURA Biosciences Inc (HURA), noting that key financial data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. It presents the stock's current price, market capitalization, and a general overvi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 08:10
- Source
- TradingKey
TradingKey
Direct company coverage
TuHURA Biosciences Inc (HURA) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of TuHURA Biosciences Inc (HURA), primarily noting the lack of essential disclosed data for profitability, operational efficiency, growth potential, and shareholder returns. It highlights the company's current market cap, stock pr
- Tone
- Negative 28/100
- Event
- Market update
- Published
- 17 Jun 2026 08:09
- Source
- TradingKey
TradingKey
Direct company coverage
TuHURA Biosciences Inc (HURA) Institutional Confidence
This article provides an "Institutional Confidence" overview for TuHURA Biosciences Inc (HURA), detailing institutional shareholdings and recent changes in those holdings. Key shareholders like Vijay Patel, Matthew Nachtrab, and Samir Rashmikant Patel are listed, along with Black
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:09
- Source
- TradingKey
Investing.com Canada
Direct company coverage
Citizens reiterates TuHURA Biosciences stock rating on AML progress By Investing.com
Citizens has reaffirmed its "Market Outperform" rating and $9.00 price target for TuHURA Biosciences (NASDAQ:HURA) after the company filed an Investigational New Drug (IND) application for its anti-VISTA monoclonal antibody, TBS-2025. This move follows FDA guidance for developing
- Tone
- Positive 69/100
- Event
- Analyst action
- Published
- 16 Jun 2026 10:39
- Source
- Investing.com Canada
Investing.com
Direct company coverage
Citizens reiterates TuHURA Biosciences stock rating on AML progress
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 16 Jun 2026 07:00
- Source
- Investing.com
grafa.com
Direct company coverage
TuHURA Biosciences (NASDAQ:HURA) files IND for TBS-2025
TuHURA Biosciences (NASDAQ:HURA) has filed an Investigational New Drug (IND) application with the FDA for its VISTA-inhibiting antibody, TBS-2025, aimed at treating specific subsets of acute myeloid leukemia (AML) and other blood-related cancers. The company plans to initiate a P
- Tone
- Positive 72/100
- Event
- Regulatory and legal
- Published
- 15 Jun 2026 14:14
- Source
- grafa.com
MT Newswires
Direct company coverage
TuHURA Biosciences Files New Drug Application for Evaluation of Antibody to Treat Subsets of AML
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 12:33
- Source
- MT Newswires
Investing.com
Direct company coverage
TuHURA files IND for TBS-2025 in blood cancer study
TuHURA Biosciences, a clinical-stage biotech company, has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, a VISTA inhibiting antibody, to treat acute myeloid leukemia and other blood cancers. The company plans to initiate a Phase 1b/2 study in the s
- Tone
- Positive 76/100
- Event
- Regulatory and legal
- Published
- 15 Jun 2026 12:14
- Source
- Investing.com